Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingcong Wang

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Haematologica|September 28, 2023
Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myelomaGege Chen, Xuejie Gao, Xinyan Jia, et al.
Cell Death & Disease|October 13, 2017
DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathwayXi Sun, Bo Li, Bingqian Xie, et al.
Journal of Translational Medicine|November 28, 2023
The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathwayYingcong Wang, Sanfeng Dong, Ke Hu, et al.
Leukemia|May 8, 2023
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myelomaLi Xu, Yingcong Wang, Guanli Wang, et al.
Theranostics|November 8, 2017
Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myelomaMinjie Gao, Bo Li, Xi Sun, et al.
Cancer Research|August 15, 2025
Editor's Note: A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma ProgressionYingcong Wang, Jing Huang, Bo Li, et al.
Cancer Research|November 17, 2019
A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma ProgressionYingcong Wang, Jing Huang, Bo Li, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Haematologica|September 28, 2023
Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myelomaGege Chen, Xuejie Gao, Xinyan Jia, et al.
Cell Death & Disease|October 13, 2017
DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathwayXi Sun, Bo Li, Bingqian Xie, et al.
Journal of Translational Medicine|November 28, 2023
The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathwayYingcong Wang, Sanfeng Dong, Ke Hu, et al.
Leukemia|May 8, 2023
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myelomaLi Xu, Yingcong Wang, Guanli Wang, et al.
Theranostics|November 8, 2017
Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myelomaMinjie Gao, Bo Li, Xi Sun, et al.
Cancer Research|August 15, 2025
Editor's Note: A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma ProgressionYingcong Wang, Jing Huang, Bo Li, et al.
Cancer Research|November 17, 2019
A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma ProgressionYingcong Wang, Jing Huang, Bo Li, et al.
Pageof 4